GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MDxHealth SA
MDxHealth is a company specializing in molecular cancer diagnostics. Its stock price reflects its efforts to increase acceptance of its prostate cancer diagnostic tests. The chart tells the story of its struggle to gain acceptance from doctors and insurance companies.
Share prices of companies in the market segment - Medanalysis
MDxHealth is a European company that develops and commercializes molecular diagnostic tests for the detection and prognosis of cancer, particularly prostate cancer. We have classified it under "Medanalysis." The chart below shows the market valuation of the oncology diagnostics sector.
Broad Market Index - GURU.Markets
MDxHealth is a European company that develops and commercializes molecular diagnostic tests for cancer detection and prognosis. As a component of the GURU.Markets index, it represents the oncology diagnostics sector. The chart below shows the US market. See how MDxHealth shares compare to the US market.
Change in the price of a company, segment, and market as a whole per day
MDXH - Daily change in the company's share price MDxHealth SA
For MDxHealth, a cancer diagnostics company, change_co is a measure of volatility in the medical technology sector. Daily fluctuations reflect the response to the acceptance of its tests and changes in pricing. This metric is important for analyzing innovative diagnostics companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
MDxHealth SA is a diagnostics company. This chart highlights the high volatility of the healthcare sector. Comparison with MDXH, which focuses on urological cancer testing, helps us understand its innovative nature.
Daily change in the price of a broad market stock, index - GURU.Markets
MDxHealth specializes in molecular cancer diagnostics, particularly prostate cancer. The company's shares fluctuate with news of its tests' acceptance by the medical community. This scientifically based volatility is part of the dynamic of the innovative healthcare sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MDxHealth SA
For MDxHealth SA, the year-over-year trend is a story of the adoption of its molecular tests for prostate cancer diagnosis. Its market capitalization growth over the past 12 months reflects the growing number of urologists using its SelectMDx and ConfirmMDx tests, which help avoid unnecessary biopsies, which is important for both patients and the healthcare system.
Annual dynamics of market capitalization of the market segment - Medanalysis
MDxHealth SA is a company specializing in molecular cancer diagnostics. Its innovative tests help doctors make decisions. This chart shows how its scientific advancements, commercialization efforts, and competition in the rapidly evolving field of genetic testing are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MDxHealth, specializing in cancer diagnostics, operates in the defensive healthcare sector. Demand for cancer tests is unaffected by economic cycles. The company's share price (ADR) reflects a long-term trend toward personalized medicine, providing it with sustainable growth potential.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MDxHealth SA
MDxHealth, a diagnostics company, depends on the adoption of its tests for its market cap. The monthly fluctuations on the chart reflect the volume of its prostate cancer tests and, more importantly, insurance reimbursement rates.
Monthly dynamics of market capitalization of the market segment - Medanalysis
MDxHealth provides molecular diagnostics services in urology, assisting in the detection of prostate cancer. The medical diagnostics sector is growing as personalized medicine advances. The industry dynamics graph demonstrates the general interest in technologies that enable more accurate diagnoses. MDxHealth strives to become the standard in its niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MDxHealth SA is a commercial molecular diagnostics company offering tests for the detection and prognosis of prostate cancer. The company's future depends on the acceptance of its tests by doctors and insurance companies. The broader market chart serves as a backdrop to assess the market penetration of its innovative diagnostic solutions, regardless of overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MDxHealth SA
MDxHealth SA is a Belgian company specializing in molecular cancer diagnostics, particularly for prostate cancer. Its weekly stock price is influenced by testing volumes, insurance coverage decisions in the US, and competition in the oncology diagnostics market.
Weekly dynamics of market capitalization of the market segment - Medanalysis
MDxHealth specializes in molecular cancer diagnostics, particularly prostate cancer. Demand for its tests depends on their acceptance by the medical community and insurance companies. This chart clearly shows how company news and test performance data impact its stock, causing it to move regardless of sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MDxHealth is a molecular diagnostics company. Its success depends on the clinical adoption of its tests, not the state of the economy. This chart shows how the company's shares have a life of their own, often ignoring overall market fluctuations.
Market capitalization of the company, segment and market as a whole
MDXH - Market capitalization of the company MDxHealth SA
The market capitalization of MDxHealth, a company specializing in molecular cancer diagnostics, reflects its focus on urology. Its price chart shows how investors assess the commercial potential of its tests, which help doctors make decisions about prostate cancer treatment. It's a bet on personalized medicine.
MDXH - Share of the company's market capitalization MDxHealth SA within the market segment - Medanalysis
MDxHealth specializes in the development and commercialization of molecular diagnostic tests for urology, particularly for prostate cancer detection. Its market share is growing. The chart shows how its tests help doctors make more informed decisions, avoiding unnecessary biopsies and improving diagnostics.
Market capitalization of the market segment - Medanalysis
Below is a chart of the total market capitalization of the oncology diagnostics sector. MDxHealth is a European company specializing in molecular tests for prostate cancer diagnostics. The size of this market reflects the enormous need for early and accurate diagnostics. MDxHealth is striving to fill this niche by offering physicians innovative tools.
Market capitalization of all companies included in a broad market index - GURU.Markets
MDxHealth is a company specializing in molecular diagnostics for cancer, particularly prostate cancer. Its tests help inform treatment decisions. The company's market capitalization reflects the importance of accurate diagnostics in oncology. The chart below shows the importance of this segment.
Book value capitalization of the company, segment and market as a whole
MDXH - Book value capitalization of the company MDxHealth SA
MDxHealth's foundation is its laboratories and intellectual property in its portfolio of molecular diagnostic tests for urologic oncology. This chart tells the story of a company commercializing its tests, turning years of R&D investment into revenue-generating assets and strengthening its balance sheet.
MDXH - Share of the company's book capitalization MDxHealth SA within the market segment - Medanalysis
MDxHealth specializes in molecular cancer diagnostics. The chart shows its share of real assets. These include its certified laboratories in Europe and the US, where cutting-edge equipment is used to conduct genetic tests that aid in treatment decisions.
Market segment balance sheet capitalization - Medanalysis
MDxHealth, a diagnostics company, is a capital-intensive business due to its need to own advanced laboratories. The graph below illustrates the scale of the entire healthcare sector, highlighting the uniqueness of its infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
MDxHealth specializes in molecular cancer diagnostics, particularly for prostate cancer. The company's assets are its laboratories. Its stake in BCap_All provides the necessary resources for conducting highly accurate tests that help doctors make critical decisions in cancer treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MDxHealth SA
MDxHealth is a molecular diagnostics company. The award to its laboratory assets reflects its portfolio of prostate cancer diagnostic tests and their potential to change the standard of care in this field.
Market to book capitalization ratio in a market segment - Medanalysis
MDxHealth provides diagnostic tests for urologic cancer. Its value lies in its proprietary tests and data. The chart shows how the market values its intellectual property and commercial potential in precision medicine, placing a premium on its laboratory assets.
Market to book capitalization ratio for the market as a whole
MDxHealth provides diagnostic tests for urologic cancer. The company's value lies in its unique technologies that help doctors make decisions. This chart illustrates how much market valuation in the advanced diagnostics space can exceed book value due to its potential to transform treatment approaches.
Debts of the company, segment and market as a whole
MDXH - Company debts MDxHealth SA
MDxHealth, a company specializing in molecular cancer diagnostics, is using capital to commercialize its tests. Its debt strategy is aimed at funding laboratory capacity, working with urologists, and insurance companies to secure reimbursement, which is key to the widespread adoption of its diagnostic products.
Market segment debts - Medanalysis
MDxHealth provides molecular diagnostics services in urology, helping to detect prostate cancer. In the field of medical diagnostics, investments in R&D and laboratory capacity are key. This chart shows how the company is funding the development and commercialization of its tests, striving to improve diagnostic accuracy and treatment standards.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MDxHealth SA
MDxHealth provides diagnostic tests for oncology. Developing and commercializing medical tests is a lengthy and costly process. This chart shows the debt-to-equity ratio, a key indicator of a company's financial strength and its reliance on external funding for research and marketing.
Market segment debt to market segment book capitalization - Medanalysis
MDxHealth SA is a European company specializing in molecular cancer diagnostics, particularly prostate cancer. This chart shows debt trends in the medical analytics sector. It allows one to assess how the company is financing the commercialization of its tests in the competitive US and European markets and how its financial policy compares to the industry.
Debt to book value of all companies in the market
MDxHealth SA is a company specializing in molecular cancer diagnostics. For companies like this, investing in R&D and commercializing their tests is key. This graph of total market debt helps us understand MDxHealth's chosen financing path. It likely relies on equity capital, and its financial structure differs significantly from the market average shown in the graph.
P/E of the company, segment and market as a whole
P/E - MDxHealth SA
MDxHealth SA is a European company specializing in molecular cancer diagnostics, particularly prostate cancer. This chart shows how the market assesses the commercial potential of its diagnostic tests. This assessment is based on the expectation that its tests will become the standard in urology, leading to increased revenue and profitability.
P/E of the market segment - Medanalysis
This chart shows the average valuation for companies in the medical diagnostics sector, providing context for MDxHealth. It reflects general expectations for the growth of personalized medicine. Comparisons with this chart help us understand whether MDxHealth's focus on prostate cancer diagnostics is viewed more or less optimistically by the market than companies with a broader testing portfolio.
P/E of the market as a whole
MDxHealth provides diagnostic tests for urology, primarily for prostate cancer. The company's success depends on physician acceptance of its tests and their inclusion in insurance coverage. This chart of overall healthcare sentiment helps understand how investors view the prospects of diagnostic companies. Do they believe demand is growing or are they wary of competition and price pressure?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MDxHealth SA
MDxHealth is a European company specializing in molecular cancer diagnostics, primarily for prostate cancer. This graph shows the expected clinical adoption of its tests. The estimate depends on testing volumes, insurance reimbursement in the US and Europe, and the ability of its products to help physicians make more informed treatment decisions.
%20P%2FE%20MDxHealth%20SA&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MDxHealth-SA&v=1772513688622 "Chart of the company's future (projected) P/E MDxHealth SA")
Future (projected) P/E of the market segment - Medanalysis
MDxHealth is a company specializing in molecular cancer diagnostics, primarily for prostate cancer. This chart reflects investor expectations for the company's profitability relative to the medical diagnostics sector. It provides insight into the market's perception of the potential of its tests to improve diagnostic accuracy and clinical decision-making.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772513688665 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
MDxHealth provides molecular diagnostics services in urology, assisting in the detection and treatment of prostate cancer. Despite the general market fluctuations shown by this chart, MDxHealth's business is driven by medical needs. Demand for its tests depends on physician recommendations and demographics (aging population), making it relatively non-cyclical.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513688697 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MDxHealth SA
MDxHealth is a European company specializing in molecular diagnostics for cancer, particularly prostate cancer. Its tests help doctors make more informed treatment decisions. This chart shows the financial results of the company, which commercializes cutting-edge genetic tests in oncology.
Profit of companies in the market segment - Medanalysis
MDxHealth specializes in molecular cancer diagnostics, primarily prostate cancer. This chart shows profitability in the medical diagnostics sector. For MDXH, this reflects the demand for non-invasive and accurate tests that aid in treatment decisions. Their tests help avoid unnecessary biopsies and select the right therapy.
Overall market profit
MDxHealth is a European company specializing in the development and commercialization of molecular diagnostic tests for oncology, primarily for prostate cancer. Its tests help doctors make more informed treatment decisions. The company's growth depends on the implementation of its tests in clinical practice. This graph does not reflect the specifics of the medical diagnostics market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MDxHealth SA
MDxHealth specializes in molecular diagnostics in urology, offering tests for prostate cancer detection and prognosis. The revenue projections presented here depend on the usage of its tests, such as SelectMDx and ConfirmMDx. Efforts to include tests in clinical guidelines are key to growth.
%20profit%20of%20the%20company%20MDxHealth%20SA&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MDxHealth-SA&v=1772513688829 "Graph of future (projected) profit of the company MDxHealth SA")
Future (predicted) profit of companies in the market segment - Medanalysis
MDxHealth SA specializes in molecular cancer diagnostics, particularly prostate cancer. The revenue forecast for this sector depends on the introduction of new diagnostic tests into clinical practice. This chart reflects analysts' expectations for growth in the non-invasive diagnostics market, which helps make more informed treatment decisions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772513688840 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
MDxHealth provides diagnostic tests for urologic cancer, helping physicians make treatment decisions. Demand depends on the adoption of these tests in clinical practice. Market revenue projections, presented here, impact healthcare budgets and the system's ability to pay for innovative diagnostics.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513688862 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MDxHealth SA
MDxHealth is a European company specializing in molecular cancer diagnostics, particularly prostate cancer. This chart shows how investors estimate its revenue from diagnostic test sales. This estimate depends on physician acceptance of its tests, insurance coverage, and competition from other diagnostic methods.
P/S market segment - Medanalysis
MDxHealth specializes in molecular diagnostics in urology, offering tests that aid in the detection and treatment of prostate cancer. Accurate diagnostics are key to success. This chart reflects the average revenue estimate for the sector, helping to understand how the market views MDxHealth's innovative diagnostic products and commercial potential.
P/S of the market as a whole
MDxHealth is a European company specializing in molecular cancer diagnostics, particularly for prostate cancer. Its tests help doctors make more informed treatment decisions. The company's growth depends on the adoption of its tests in clinical practice. This chart provides an overview of the market's perception of revenue prospects in the innovative medical diagnostics sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MDxHealth SA
MDxHealth specializes in molecular cancer diagnostics, primarily urologic. This chart shows how investors estimate the company's future revenue from sales of its diagnostic tests. It reflects the growing need for accurate and non-invasive cancer detection methods.
%20P%2FS%20MDxHealth%20SA&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MDxHealth-SA&v=1772513689025 "The graph of the company's future (projected) P/S MDxHealth SA")
Future (projected) P/S of the market segment - Medanalysis
MDxHealth SA specializes in molecular diagnostics for urology, offering tests that aid in the detection and treatment of prostate cancer. This chart reflects how the market perceives its innovative diagnostic products and their potential to become a standard in urological practice, improving patient outcomes.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772513689062 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
MDxHealth provides diagnostic tests for urologic cancer, helping physicians make treatment decisions. Demand for their products depends on the number of biopsies performed and the acceptance of their tests. This graph, reflecting the state of the healthcare system, is important. Economic stability ensures funding for medical procedures and the willingness of clinics to implement new diagnostic methods.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513689129 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MDxHealth SA
MDxHealth is a company specializing in molecular diagnostics for urological cancers. Its tests help doctors make treatment decisions for prostate cancer. This chart shows revenue from these tests. Sales growth depends on how widely urologists implement its diagnostic tests in their clinical practice.
Sales of companies in the market segment - Medanalysis
MDxHealth is a company specializing in molecular diagnostics for urologic cancers. Their tests, such as SelectMDx and ConfirmMDx for prostate cancer, help doctors make more informed treatment decisions. Their revenue comes from providing these high-tech diagnostic services.
Overall market sales
MDxHealth specializes in the development and commercialization of molecular diagnostic tests for the detection and monitoring of cancer, particularly prostate cancer. Its tests help physicians make more informed treatment decisions. This total revenue chart includes the healthcare sector, where MDXH contributes to the advancement of personalized medicine in oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MDxHealth SA
MDxHealth is a European company specializing in molecular cancer diagnostics, particularly prostate cancer. Its tests help doctors decide whether a biopsy is necessary. This chart shows analysts' expectations for the adoption of its diagnostic tests in urology practice, which determines future revenue.
%20sales%20of%20the%20company%20MDxHealth%20SA&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MDxHealth-SA&v=1772513689400 "Schedule of future (projected) sales of the company MDxHealth SA")
Future (projected) sales of companies in the market segment - Medanalysis
MDxHealth specializes in molecular cancer diagnostics, offering tests that help doctors make treatment decisions for prostate cancer. This chart shows forecasts for the entire oncology diagnostics market. It reflects the growing need for more accurate and less invasive tests for early detection and personalized cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772513689424 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
MDxHealth, a company specializing in molecular cancer diagnostics, sees this chart as an indicator of investment in preventive medicine. Rising overall economic forecasts are allowing healthcare systems to focus more on early detection. This is driving demand for MDxHealth's advanced tests, which help inform prostate cancer treatment decisions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513689473 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MDxHealth SA
MDxHealth provides molecular diagnostics services in urology, helping to detect prostate cancer. The company's profitability depends on the number of tests performed and the level of reimbursement from insurance companies. This chart illustrates how successfully the company commercializes its diagnostic tests, balancing R&D and operating revenue.
Market segment marginality - Medanalysis
MDxHealth specializes in molecular cancer diagnostics, specifically providing prostate cancer screening tests. This indicator reflects the commercial value of its diagnostic services. This high result demonstrates the clinical utility of its tests and their integration into standard urological practice.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company MDxHealth SA
MDxHealth specializes in molecular diagnostics in urology, offering tests that aid in the detection and treatment of prostate cancer. This graphic shows the team of scientists and sales specialists developing and promoting these innovative diagnostic tools to urologists.
Share of the company's employees MDxHealth SA within the market segment - Medanalysis
MDxHealth SA specializes in molecular diagnostics for urology, offering tests that aid in the detection and treatment of prostate cancer. Developing and implementing such precise genetic tests requires a team of highly qualified scientists and laboratory technicians. This chart reflects its scientific leadership in its field, demonstrating the concentration of talent in the field of urological diagnostics.
Number of employees in the market segment - Medanalysis
MDxHealth specializes in molecular cancer diagnostics, primarily in urology (prostate cancer). The company's tests help doctors make more informed treatment decisions. This graphic shows the team of scientists and sales specialists promoting cutting-edge diagnostic tools that help avoid unnecessary biopsies and select the optimal treatment strategy.
Number of employees in the market as a whole
MDxHealth SA is a company specializing in molecular cancer diagnostics. While their work is laboratory-based, the economic context, reflected in this graph, is important. A stable labor market ensures funding for healthcare systems and broad insurance coverage, making advanced diagnostic tests like MDxHealth's accessible to more patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MDxHealth SA (MDXH)
MDxHealth SA is a company specializing in molecular cancer diagnostics. This chart reflects the value of their tests and technologies. Their high market capitalization per employee indicates that the market values their intellectual property. A small team of scientists creates diagnostic tools that could save thousands of lives.
%20of%20the%20company%20MDxHealth%20SA%20(MDXH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MDxHealth-SA-MDXH&v=1772513689900 "Chart of market capitalization per employee (in thousands of dollars) of the company MDxHealth SA (MDXH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
MDxHealth SA is a molecular diagnostics company specializing in cancer detection tests. Its value lies in its research and patents. This chart shows the market valuation of its diagnostic platform per employee, allowing for comparison with other biotech companies.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772513690004 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
MDxHealth is a European company specializing in molecular cancer diagnostics, particularly prostate cancer. In the medical diagnostics industry, this indicator reflects the value of its tests. It shows how the market perceives its ability to provide doctors with information that helps them make more accurate treatment decisions.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513690039 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MDxHealth SA (MDXH)
MDxHealth is a European company specializing in molecular diagnostics for cancer (primarily prostate cancer). This chart shows how their lab monetizes its proprietary tests (ConfirmMDx, SelectMDx). Profitability depends entirely on how often doctors prescribe their tests and how well insurance companies reimburse them.
%20Chart%20MDxHealth%20SA%20(MDXH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MDxHealth-SA-MDXH&v=1772513690059 "Company Profit Per Employee (in thousands of dollars) Chart MDxHealth SA (MDXH)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
MDxHealth SA is a molecular diagnostics company specializing in cancer, particularly urological cancer (prostate cancer). They provide tests that help doctors make treatment decisions. This chart represents an industry benchmark. In diagnostics, it reflects how successfully the company commercializes its tests while managing laboratory and sales team costs for urologists.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772513690093 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
MDxHealth is a European diagnostic company focused on cancer (primarily prostate cancer). They offer genetic tests (e.g., SelectMDx, ConfirmMDx) that help doctors decide whether to perform a biopsy. They are a laboratory-based business. This chart shows how efficiently their team (lab technicians and sales) can process tests and receive reimbursement from insurance companies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513690112 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MDxHealth SA (MDXH)
MDxHealth provides diagnostic tests for urologic cancer. This chart shows how the company is commercializing its medical innovations. The increase in revenue per employee reflects the increased volume of tests (such as SelectMDx and ConfirmMDx) and their integration into clinical practice to improve prostate cancer diagnosis.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MDxHealth-SA-MDXH&v=1772513690151 "Sales chart per company employee MDxHealth SA (MDXH)")
Sales per employee in the market segment - Medanalysis
MDxHealth is a European diagnostic company focused on urology tests (prostate cancer). Their business consists of R&D and laboratory operations. This chart shows how productive their specialized laboratory services are in generating revenue per employee (laboratory technician, scientist) compared to other diagnostic companies.
Sales per employee for the market as a whole
MDxHealth is a molecular diagnostics company specializing in cancer, primarily prostate cancer. Their tests help doctors decide whether a biopsy is necessary. Their business is their laboratory and R&D. This chart shows how effectively their team of scientists and lab technicians monetizes these specialized tests.
Short shares by company, segment and market as a whole
Shares shorted by company MDxHealth SA (MDXH)
MDxHealth (MDXH) is a molecular diagnostics company specializing in the development of tests (e.g., ConfirmMDx, SelectMDx) for prostate cancer. This chart shows bearish bets. The rise in shorts may reflect investor doubts that their tests will gain widespread acceptance among doctors and insurance companies, or the intense competition in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MDxHealth-SA-MDXH&v=1772513690244 "Short Shares Chart for the Company MDxHealth SA (MDXH)")
Shares shorted by market segment - Medanalysis
MDxHealth (MDXH) is a Belgian company specializing in molecular cancer diagnostics, particularly for prostate cancer (SelectMDx and ConfirmMDx tests). This chart highlights the general skepticism in the medical diagnostics sector. It summarizes downside bets, reflecting investor concerns about changes in the reimbursement system or competition.
Shares shorted by the overall market
MDxHealth provides advanced diagnostic tests in urology, specifically for prostate cancer detection. This is a critically important and in-demand medical service. Patient demand for cancer diagnostics is independent of the economic situation, providing the company with strong protection against the general market panic demonstrated by this chart.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MDxHealth SA (MDXH)
MDxHealth (MDXH) is a Belgian company specializing in molecular diagnostics (MDx) for cancer, primarily prostate cancer. Their tests (SelectMDx, ConfirmMDx) help doctors make biopsy decisions. This chart measures momentum. It shows "overbought" (above 70) due to strong test adoption data or "oversold" (below 30) due to reimbursement issues.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MDxHealth-SA-MDXH&v=1772513690309 "RSI 14 indicator chart for the company's stock MDxHealth SA (MDXH)")
RSI 14 Market Segment - Medanalysis
MDxHealth (MDXH) is a molecular diagnostics company focused on prostate cancer. Their tests (SelectMDx, ConfirmMDx) help doctors decide whether a biopsy is necessary. This chart measures the pulse of the Medical Analysis sector. It helps investors understand whether MDXH's performance reflects their tests or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
MDxHealth (MDXH) provides diagnostic tests. This chart shows that its business is "defensive." Demand for diagnostics (for urology) is unaffected by euphoria or panic. During periods of market panic, investors seek safe havens in companies with completely non-cyclical demand.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MDXH (MDxHealth SA)
MDxHealth is a molecular diagnostics company specializing in prostate cancer screening tests (such as SelectMDx) that help urologists make biopsy decisions. This chart shows analysts' 12-month target price estimates based on testing volume and insurance coverage.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MDXH-MDxHealth-SA&v=1772513690427 "A chart showing analyst consensus forecasts for the expected stock price. MDXH (MDxHealth SA)")
The difference between the consensus estimate and the actual stock price MDXH (MDxHealth SA)
MDxHealth is a Belgian molecular diagnostics company. They specialize in noninvasive tests (urine and blood) for cancer detection and prognosis, primarily prostate cancer (SelectMDx and ConfirmMDx tests). This chart shows analysts' confidence in the commercialization and reimbursement of their tests.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MDXH-MDxHealth-SA&v=1772513690516 "A chart showing the difference between the consensus forecast and the actual stock price. MDXH (MDxHealth SA)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
MDxHealth is a European company specializing in molecular diagnostics for prostate cancer. Its tests help doctors determine whether a patient needs a biopsy. This chart shows analysts' overall expectations for the entire medical testing sector. It reflects whether experts believe the market for "precision" diagnostics in urology will grow.
Analysts' consensus forecast for the overall market share price
MDxHealth SA is a Belgian company specializing in molecular diagnostics (tests) for urology. Their tests help doctors make decisions about prostate cancer treatment. This chart shows overall market sentiment. For MDxHealth, which operates in the protective healthcare sector, overall optimism is important for funding, but their growth depends more on the acceptance of their tests by insurance companies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MDxHealth SA
MDxHealth is a smart lab for urologists. They offer advanced molecular (genetic) tests (SelectMDx, ConfirmMDx) that help doctors determine prostate cancer risk and avoid unnecessary biopsies. This chart summarizes their commercialization, reflecting the volume of tests performed and their difficult battle for reimbursement from insurance companies (Medicare).
AKIMA Market Segment Index - Medanalysis
MDxHealth is a company specializing in molecular cancer diagnostics, specifically developing noninvasive tests for prostate cancer. This chart shows the average index for the medical analysis sector. It allows you to assess how MDxHealth's diagnostic tests compare to the average of competitors.
The AKIM Index for the overall market
MDxHealth is a molecular diagnostics company specializing in urology (prostate cancer). It provides genomic tests for clinical decision-making. This chart, reflecting the market average, provides context. It helps assess how this commercialization story in diagnostics compares to overall macroeconomic trends in healthcare.
